Immunocore Holdings (IMCR) Profit After Tax (2021 - 2026)
Immunocore Holdings (IMCR) posted Profit After Tax of $13.0 million for Q1 2026, up 143.15% sequentially from -$30.1 million in Q4 2025, and up 127.72% YoY from $5.7 million in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Profit After Tax (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Profit After Tax for 6 years, with the latest figure at $13.0 million in Q1 2026.
- Quarterly Profit After Tax rose 127.72% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.0 million (down 74.82% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
- Profit After Tax grew to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
- Over five years, Profit After Tax peaked at $13.0 million in Q1 2026 and troughed at -$30.1 million in Q4 2025.
- A 5-year average of -$11.6 million and a median of -$15.5 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 291.35% in 2023, then surged 185.32% in 2024.
- Over 5 years, Profit After Tax stood at -$29.6 million in 2022, then soared by 35.78% to -$19.0 million in 2023, then fell by 25.22% to -$23.8 million in 2024, then retreated by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $13.0 million, -$30.1 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 971.91 Mn | 114.84 Mn | -808,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -808,000.00 |
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 5.02 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 11.98 Mn |
| Jun 30, 2024 | -11.62 Mn |
| Mar 31, 2024 | -24.44 Mn |
| Dec 31, 2023 | -18.98 Mn |
| Sep 30, 2023 | -14.05 Mn |
| Jun 30, 2023 | -17.01 Mn |
| Mar 31, 2023 | -19.45 Mn |
| Dec 31, 2022 | -29.56 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -20.31 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |